China Cord Blood Corporation 2011 second quarter net revenue increases 29.4% to RMB82.7 million

NewsGuard 100/100 Score

China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the second quarter and first half of fiscal 2011 ended September 30, 2010.

Second Quarter of Fiscal 2011 Highlights

  • Net revenue increased 29.4% to RMB82.7 million ($12.4 million).
  • New subscriber sign-ups grew 22.5% to 13,932.
  • Gross profit increased 37.3% to RMB63.5 million ($9.5 million).
  • Gross margin expanded more than 4 percentage points to 76.8%.
  • Operating income increased 20.9% to RMB29.2 million ($4.4 million).
  • Net income attributable to shareholders increased 24.6% to RMB22.0million ($3.3 million).

First Half of Fiscal 2011 Highlights

  • Net revenue increased 26.7% to RMB154.4 million ($23.1 million).
  • New subscriber sign-ups grew 20.0% to 26,112.
  • Gross profit increased 34.2% to RMB118.0 million ($17.6 million).
  • Gross margin expanded more than 4 percentage points to 76.4%.
  • Operating income increased 11.3% to RMB52.5 million ($7.9 million).
  • Net income attributable to shareholders reached RMB39.6 million ($5.9 million).

Ms. Ting Zheng, Chairperson and Chief Executive Officer of China Cord Blood Corporation, commented, "We are very pleased with our solid performance in the second quarter of fiscal 2011, which reflects our ongoing achievements to continuously penetrate our Beijing and Guangdong market.  It was also the first time our quarterly new subscriber numbers exceeded the 13,000 mark and set new records in terms of revenue and profit.  Alongside our encouraging sales performance, margins also improved on the back of economies of scale and the recurring storage fee revenue of our business.  We are even more excited by the fact that general public in Beijing and Guangdong is becoming increasingly receptive towards umbilical cord blood stem cells banking services.  In view of China's one-child policy, one-license per region regime and over 1.2 million babies born in Beijing and Guangdong each year, we are confident in setting new records for the future quarters to come."  

Second Quarter Fiscal 2011 Financial Results

REVENUE. Second quarter revenue increased 29.4% to RMB82.7 million ($12.4 million), up from RMB63.9 million in the same period last year.  Revenue from processing fee increased by 24.4% to RMB65.6 million ($9.8 million) as the number of new subscribers signed up during the second quarter increased by 22.5% to 13,932.  Revenue from storage fees increased 53.2% year-over-year to RMB17.1 million ($2.6 million) and the accumulated subscriber base as of September 30, 2010 reached 155,424, up 46.9% year-over-year. Revenue from storage fee accounted for 20.6% of the total second quarter revenue, compared to 17.4% in the same period last year.

GROSS PROFIT. Second quarter gross profit increased to RMB63.5 million ($9.5 million), up 37.3% from RMB46.3 million in the same period last year. Aside from the strong revenue growth we also benefited economies of scale and an increase in revenue from storage fees which resulted more than four percentage points margin expansion to 76.8%.

OPERATING INCOME. Operating income reached RMB29.2 million ($4.4 million), up 20.9% from RMB24.1 million. The increase in operating income was largely attributable to robust revenue growth and favorable margin expansion. Operating income as a percentage of revenues stood at 35.3%, representing a steady sequential improvement.

Research and Development expense. Second quarter research and development expense amounted to RMB1.8 million ($0.3 million) due to the Company's effort aimed to improve cost structure and operational efficiency.

Sales and Marketing expense. Consistent with the ongoing effort to broaden market coverage and deepen market penetration, second quarter sales and marketing expense increased 23.4% to RMB11.7 million ($1.7 million). It also reflected the Company's commitment to support rising demand and sales activities. With management's effective cost control effort and robust revenue growth, sales and marketing expense as a percentage of revenue remained stable at 14.1%.  

General Administrative expense. Second quarter general administration expenses amounted to RMB20.9 million ($3.1 million). General administrative expense as a percentage of revenue retreated to 25.2%. Management effort to monitor and control overall administrative expense has yielded preliminary success and overall administrative expense remains stable on a quarter on quarter basis.  

NET INCOME ATTRIBUTABLE TO SHAREHOLDERS. Second quarter net income attributable to shareholders reached RMB22.0 million ($3.3 million).  Net margin for the second quarter of fiscal 2011 was 26.6% which also represented a steady improvement sequentially. Basic earnings per share for second quarter of fiscal 2011 were RMB0.33 ($0.05).

NET CASH. As of September 30, 2010, the Company had cash and cash equivalents of RMB338.6 million ($50.6 million), compared to RMB280.8 million as of March 31, 2010. As of September 30, 2010, total borrowing was RMB45 million ($6.7 million).

Ms. Zheng concluded, "Our solid track record is a strong testimony with respect to our ability to commercialize, penetrate, and grow our business.  As we continue to penetrate the Beijing and Guangdong market, we also invested in the Shandong cord blood bank and have executed geographical expansion initiative by securing our position for Zhejiang province.  Being the only operator with multiple licenses reflected our competitive advantage to seize merger and acquisition opportunities and our management team's ability to commercialize the cord blood banking services in new regions.  As strong growth is expected from existing Beijing municipality and Guangdong province and in the future Zhejiang province, we will also monitor other emerging opportunities both inside and outside of China."

First Half Fiscal 2011 Financial Results

For first half of fiscal 2011, total revenue increased 26.7% to RMB154.4 million ($23.1 million), from RMB121.8 million last year. The increase was largely attributable to the 20.0% increase in new subscriber numbers to 26,112 new subscribers and the expansion in the accumulated subscriber base to 155,424 subscribers. During the first half of the year, processing fees and storage fees grew 20.5 % and 57.6%, respectively. Gross profit in the first half of fiscal 2011 increased 34.2% to RMB118.0 million ($17.6 million) from RMB 87.9 million in the prior year period.  In the first half of fiscal 2011, operating income increased to RMB52.5 million ($7.9 million). First half fiscal 2011 net income attributable to shareholders was RMB39.6 million ($5.9 million). Basic earnings per share attributable to ordinary shares were RMB0.59 ($0.09).

Financial Outlook

The Company reaffirms its previously issued guidance and expects the number of new subscribers for the fiscal year 2011 to exceed 58,000, which would translate into at least a 30% increase in net revenue.  The management team also expects to have an accumulated total number of at least 187,000 subscribers at the end of fiscal 2011.

Source:

China Cord Blood Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing diabetes management with reliable blood glucose monitoring without finger pricking